AngioDynamics (NASDAQ:ANGO) is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products. Within the peripheral vascular business, the company’s product line features angioplasty balloons, specialty peripheral catheters and ancillary devices used to treat arterial and venous diseases. The interventional oncology division provides percutaneous ablation systems, biopsy needles and oncology-directed fluid management products to support the treatment of kidney, liver and lung tumors through image-guided therapies.
Founded in 1998 under the name UltraSound Device, Inc., the company adopted the AngioDynamics name later that year as it broadened its product focus beyond ultrasound-guided biopsy devices. Over the years, AngioDynamics has expanded through both organic growth and targeted acquisitions, incorporating established technologies to strengthen its oncology and vascular portfolios. Notable transactions include the acquisition of RITA Medical Systems’ oncology assets and the purchase of Visualase, both intended to deepen its interventional oncology offering.
AngioDynamics markets its products in more than 80 countries through direct sales teams and distribution partnerships, with operations spanning North America, Europe, Asia-Pacific and Latin America. The company serves a diverse customer base of hospitals, specialty clinics and physician offices. AngioDynamics is led by President and Chief Executive Officer Jim Clemmer, with co-founder Joseph P. Tomkin serving as Executive Chairman of the Board.
